H-CYTE, Inc. (HCYT)
| Previous Close | 1.5505 |
| Open | 1.5500 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 1.5500 - 1.8500 |
| 52 Week Range | 1.4750 - 31.9000 |
| Volume | |
| Avg. Volume | 107 |
| Market Cap | 883,578 |
| Beta (5Y Monthly) | 0.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0410 |
| Earnings Date | May 02, 2023 - May 08, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
H-CYTE Completes Acquisition of SkinDisc™ Regenerative Tissue Kit from Scion Solutions, LLC
Wound Healing and Limb Salvage Technology Added to Growing Asset PortfolioCompany’s Second Completed Transaction in Four Months TAMPA, Fla., Dec. 29, 2022 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company, announced today that the Company completed its acquisition of SkinDisc™. Highlights: SkinDisc™ acquisition further diversifies H-CYTE’s asset portfolioEarly clinical outcomes of SkinDisc™ application demonstrated significant results relative to current treatment opt
- GlobeNewswire
H-CYTE Announces Intent to Acquire SkinDisc, Expects to Complete Within 30 Days
Wound Healing and Limb Salvaging Technology Adds to Company’s Asset Portfolio Focused on Unmet Medical NeedsTAMPA, Fla., Sept. 19, 2022 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company, announced today that the Company has entered into a letter of intent to acquire SkinDisc, a patent pending tissue regeneration technology, that is expected to close within the next 30 days. Highlights: Further supports H-CYTE’s vision to build a diverse asset portfolio and transform i
- GlobeNewswire
H-CYTE Completes Acquisition of Jantibody
Milestone Achieved as Immunotherapeutic Agent Under Investigation for the Treatment of Ovarian Cancer Added to Asset PortfolioTAMPA, Fla., Sept. 08, 2022 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company, announced today that the Company completed the acquisition of Jantibody. Highlights: Jantibody allows H-CYTE to diversify its asset portfolioFocus indication for ovarian cancer with the potential to be used for other diseases such as mesothelioma and pancreatic cance
